Intuitive Surgical Inc ISRG
We take great care to ensure that the data presented and summarized in this overview for INTUITIVE SURGICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ISRG
View all-
Vanguard Group Inc Valley Forge, PA32.2MShares$16.6 Billion0.3% of portfolio
-
Black Rock Inc. New York, NY30.1MShares$15.5 Billion0.31% of portfolio
-
State Street Corp Boston, MA15.3MShares$7.89 Billion0.32% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD14.5MShares$7.46 Billion0.87% of portfolio
-
Jpmorgan Chase & CO New York, NY10.1MShares$5.23 Billion0.43% of portfolio
-
Geode Capital Management, LLC Boston, MA7.76MShares$4 Billion0.32% of portfolio
-
Capital World Investors Los Angeles, CA7.43MShares$3.83 Billion0.61% of portfolio
-
Morgan Stanley New York, NY5.82MShares$3 Billion0.22% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa4.87MShares$2.51 Billion1.03% of portfolio
-
Norges Bank Oslo, Q84.6MShares$2.37 Billion0.33% of portfolio
Latest Institutional Activity in ISRG
Top Purchases
Top Sells
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Insider Transactions at ISRG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
May 01
2025
|
Jami K Nachtsheim Director |
SELL
Open market or private sale
|
Direct |
2,400
-27.36%
|
$1,248,000
$520.0 P/Share
|
|
May 01
2025
|
Jami K Nachtsheim Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+21.48%
|
$216,000
$90.49 P/Share
|
|
Apr 30
2025
|
Amy L Ladd Director |
SELL
Open market or private sale
|
Direct |
8,776
-55.12%
|
$4,431,880
$505.55 P/Share
|
|
Apr 30
2025
|
Amy L Ladd Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,776
+35.5%
|
$2,044,808
$233.6 P/Share
|
|
Apr 29
2025
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
188
-3.47%
|
$96,256
$512.9 P/Share
|
|
Apr 29
2025
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
188
+3.36%
|
$39,104
$208.9 P/Share
|
|
Apr 28
2025
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
188
-3.47%
|
$96,820
$515.91 P/Share
|
|
Apr 28
2025
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
188
+3.36%
|
$54,520
$290.33 P/Share
|
|
Apr 25
2025
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
614
-2.85%
|
$314,982
$513.18 P/Share
|
|
Apr 25
2025
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
614
+2.77%
|
$158,412
$258.32 P/Share
|
|
Apr 25
2025
|
Myriam Curet EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-91.89%
|
$2,052,000
$513.18 P/Share
|
|
Apr 25
2025
|
Myriam Curet EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+47.89%
|
$968,000
$242.34 P/Share
|
|
Apr 25
2025
|
Gary Loeb EVP & Chief Legal and Complian |
SELL
Open market or private sale
|
Direct |
1,700
-43.09%
|
$872,100
$513.18 P/Share
|
|
Apr 25
2025
|
Jami K Nachtsheim Director |
BUY
Exercise of conversion of derivative security
|
Direct |
739
+10.39%
|
-
|
|
Apr 25
2025
|
Lewis Chew Director |
BUY
Exercise of conversion of derivative security
|
Direct |
739
+48.55%
|
-
|
|
Apr 25
2025
|
Amal M Johnson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
739
+5.37%
|
-
|
|
Apr 25
2025
|
Monica P Reed Director |
BUY
Exercise of conversion of derivative security
|
Direct |
739
+23.96%
|
-
|
|
Apr 25
2025
|
Craig H Barratt Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,043
+3.69%
|
-
|
|
Apr 25
2025
|
Amy L Ladd Director |
BUY
Exercise of conversion of derivative security
|
Direct |
739
+34.39%
|
-
|
|
Apr 25
2025
|
Sreelakshmi Kolli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
739
+43.02%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 264K shares |
|---|---|
| Grant, award, or other acquisition | 53.5K shares |
| Open market or private sale | 248K shares |
|---|---|
| Payment of exercise price or tax liability | 55.2K shares |
| Bona fide gift | 19.9K shares |